Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial
Authors:
- Andreas RilligARAndreas Rillig
- Lars EckardtLELars Eckardt
- A John CammACA John Camm
- Harry J G M CrijnsHCHarry J G M Crijns
- Andreas GoetteAndreas Goette
- Günter BreithardtGBGünter Breithardt
- Marc D LemoineMLMarc D Lemoine
- Andreas MetznerAMAndreas Metzner
- Laura RottnerLRLaura Rottner
- Ulrich SchottenUSUlrich Schotten
- Eik VettorazziEVEik Vettorazzi
Open Access
- 4 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (6)
Abstract
Clinical concerns exist about the potential proarrhythmic effects of the sodium channel blockers (SCBs) flecainide and propafenone in patients with cardiovascular disease. Sodium channel blockers were used to deliver early rhythm control (ERC) therapy in EAST-AFNET 4. We analysed the primary safety outcome (death, stroke, or serious adverse events related to rhythm control therapy) and primary efficacy outcome (cardiovascular death, stroke, and hospitalization for worsening of heart failure (HF) or acute coronary syndrome) during SCB intake for patients with ERC (n = 1395) in EAST-AFNET 4. The protocol discouraged flecainide and propafenone in patients with reduced left ventricular ejection fraction and suggested stopping therapy upon QRS prolongation >25% on therapy. Flecainide or propafenone was given to 689 patients [age 69 (8) years; CHA2DS2-VASc 3.2 (1); 177 with HF; 41 with prior myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention; 26 with left ventricular hypertrophy >15 mm; median therapy duration 1153 [237, 1828] days]. The primary efficacy outcome occurred less often in patients treated with SCB [3/100 (99/3316) patient-years] than in patients who never received SCB [SCBnever 4.9/100 (150/3083) patient-years, P < 0.001]. There were numerically fewer primary safety outcomes in patients receiving SCB [2.9/100 (96/3359) patient-years] than in SCBnever patients [4.2/100 (135/3220) patient-years, adjusted P = 0.015]. Sinus rhythm at 2 years was similar between groups [SCB 537/610 (88); SCBnever 472/579 (82)]. Long-term therapy with flecainide or propafenone appeared to be safe in the EAST-AFNET 4 trial to deliver effective ERC therapy, including in selected patients with stable cardiovascular disease such as coronary artery disease and stable HF. Clinical Trial Registration ISRCTN04708680, NCT01288352, EudraCT2010-021258-20, www.easttrial.org SCB, sodium channel blocker; ERC, early rhythm control; HF, heart failure; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; LVH, left ventricular hypertrophy; SR, sinus rhythm.Keywords
Funding Information
- German Ministry of Education and Research (01 GI 0204)
- German Centre for Cardiovascular Research
- Atrial Fibrillation Network
- European Heart Rhythm Association
- St. Jude Medical
- Abbott
- Sanofi
- German Heart Foundation
- European Union (633196, EU IMI 116074, 965286)
- British Heart Foundation (FS/13/43/30324, PG/17/30/32961, PG/20/22/35093, AA/18/2/34218)
- Leducq Foundation
This publication has 32 references indexed in Scilit:
- Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic DrugsCirculation: Cardiovascular Quality and Outcomes, 2015
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryCirculation, 2014
- Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractorinessEP Europace, 2013
- Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trialThe Lancet, 2012
- Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillationEP Europace, 2010
- Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillationBasic Research in Cardiology, 2005
- Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytesNaunyn-Schmiedeberg's Archives of Pharmacology, 2000
- Divergent Effect of Acute Ventricular Dilatation on the Electrophysiologic Characteristics of d,I‐Sotalol and Flecainide in the Isolated Rebbit heartJournal of Cardiovascular Electrophysiology, 1998
- Effect of the Antiarrhythmic Agent Moricizine on Survival after Myocardial InfarctionNew England Journal of Medicine, 1992
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991